VEGFC Protein, Human, Recombinant (His)

Vascular endothelial growth factor C (VEGF-C) is a member of the VEGF family. Upon biosynthesis, VEGF-C protein is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF-C protein is a dimeric glycoprotein, as a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. VEGF-C may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis. VEGF-C protein is over-expressed in various human cancers including breast cancer and prostate cancer. VEGF-C/VEGFR-3 axis, through different signaling pathways, plays a critical role in cancer progression by regulating different cellular functions, such as invasion, proliferation, and resistance to chemotherapy. Thus, targeting the VEGF-C/VEGFR-3 axis may be therapeutically significant for certain types of tumors.

Pack Size	Availability	Price/USD
5 μg	In stock	$ 57.00
10 μg	5 days	$ 83.00
20 μg	5 days	$ 122.00
50 μg	5 days	$ 201.00
100 μg	5 days	$ 296.00

Pack Size

Availability

Price/USD

Quantity

5 μg

In stock

$ 57.00

10 μg

5 days

$ 83.00

20 μg

5 days

$ 122.00

50 μg

5 days

$ 201.00

100 μg

5 days

$ 296.00

Biological Information

1. Measured by its binding ability in a functional ELISA. Immobilized VEGF C-his at 2 μg/mL (100 μL/well) can bind VEGFR3 hFc, the EC50 of VEGFR3 hFc is 2-15 ng/mL. 2. Scatchard analysis showed the affinity constant (Kd) of recombinant human VEGF-C bound to recombinant human VEGFR3 was 1.4 nM. 3. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 0.1-0.5 μg/mL. 4. Captured VEGFR3/FLT4 Protein, Human on anti-Human IgG Fc via CM5 Chip can bind VEGF-C with an affinity constant of 31.82 pM as determined in a SPR assay (Routinely tested).

Description

Species	Human
Expression System	HEK293
Tag	His
Accession Number	P49767
Synonyms	LMPH1D, VEGF-C, Flt4-L, vascular endothelial growth factor C, VRP
Construction	A DNA sequence encoding the mature form of human VEGFC (NP_005420.1) (Thr103-Arg227) was expressed with a C-terminal polyhistidine tag.
Protein Purity	> 95 % as determined by SDS-PAGE
Molecular Weight	Approxiamtely 15.5 kDa

Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Formulation	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
Reconstitution	A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
Stability & Storage	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Vascular endothelial growth factor C (VEGF-C) is a member of the VEGF family. Upon biosynthesis, VEGF-C protein is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF-C protein is a dimeric glycoprotein, as a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. VEGF-C may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis. VEGF-C protein is over-expressed in various human cancers including breast cancer and prostate cancer. VEGF-C/VEGFR-3 axis, through different signaling pathways, plays a critical role in cancer progression by regulating different cellular functions, such as invasion, proliferation, and resistance to chemotherapy. Thus, targeting the VEGF-C/VEGFR-3 axis may be therapeutically significant for certain types of tumors.